Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1335-1339

  Fujiwara, Yoshiyuki ^a   Nishida, Toshiro ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Yamamoto, Kazuyoshi ^a   Moon, Jeong Ho ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cytology; Gastric cancer; Neoadjuvant chemotherapy; Peritoneal dissemination

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOCETAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASCITES FLUID CYTOLOGY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLOGY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; GASTRECTOMY; HUMAN; LAPAROSCOPY; LEUKOPENIA; LOCAL ANESTHESIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERITONEUM LAVAGE; PERITONEUM METASTASIS; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH CANCER; TREATMENT DURATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; OXONIC ACID; PERITONEAL NEOPLASMS; REMISSION INDUCTION; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR;

EID: 77953787935     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Dupont JB, Lee JR, Burton GR and Cohn I Jr: Adenocarcinoma of the stomach: review of 1497 cases. Cancer 41: 941-947, 1978.
3. Yamada E, Miyaishi S, Nakazato H, Kato K, Kito T, Takagi H, Yasue M, Kato T, Morimoto T and Yamauchi M: The surgical treatment of cancer of the stomach. Int Surg 65: 387-399, 1980.
4. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G and Miwa K: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 178: 256-262, 1999.
5. Benevolo M: Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol 16: 3406-3411, 1998.
6. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A and Hiraoka H: Prognostic significance of intra-peritoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 108: 236-238, 1984. (Pubitemid 14057507)
7. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, 2nd English version. Gastric Cancer 1: 10-24, 1998.
8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction: N Engl J Med 345: 725-730, 2001.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ and MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
10. jani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274, 1988.
11. inzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA and Benson AB 3rd: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87-93, 1996.
12. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T and Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother pp. 1033-1038, 1994.
13. Taguchi T, Tsukagoshi S, Furue H, Niitani H and Noda K: Phase I clinical study of oxaliplatin. Jpn J Cancer Chemother 25: 1899-1907, 1998.
14. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1(1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
15. Liu C, Sun Q, Hang X, Zhong B and Wang D: Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs 19: 825-831, 2008.
16. Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Hidemura A, Kaisaki S and Nagawa H: Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 76(5): 311-314, 2009.
17. Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M and Ohta T Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep 19(5): 1305-1310, 2008.
18. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006.
19. Yano M, Yasuda T, Fujiwara Y, Takiguchi S, Miyata H and Monden M: Preoperative intraperitoneal chemotherapy for patients with serosa-infiltrating gastric cancer. J Surg Oncol 88(1): 39-43, 2004.
20. Yoo CH, Noh SH, Shin DW, Choi SH and Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 87: 236-242, 2000.
21. Tateishi M, Ichiyoshi Y, Kawano T, Toda T, Minamisono Y and Nagasaki S: Recurrence pattern of digestive tract carcinoma in the Japanese: comparison of gastric cancer to colon cancer. Int Surg 80: 41-44, 1995.
22. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LI, Walker JL, Burger RA and Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43, 2006.
23. Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, Hibi K, Nakao A and Tatematsu M: Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 27: 637-644, 2005.
24. Markman M, Brady MF, Spirtos NM, Hanjani P and Rubin SC: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 16(8): 2620-2624, 1998. (Pubitemid 28363024)
25. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S and Monden M: Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology 64(2): 176-182, 2003.
26. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1851, 2004.